BIOPHARMA
By
What Lessons from Sanofi’s 2025 Execution Signal Its Future in Oncology, Immunology, and Vaccines?
Sanofi concluded 2025 with a combination of solid portfolio performance, strategic execution, and continued innovation across its pharmaceuticals,…
How Did Roche’s 2025 Deals Shape Its Strategy and Future Outlook?
In 2025, Roche executed a series of focused deals and collaborations designed to strengthen its scientific platforms, expand…
How Did Roche Navigate 2025 and What Lies Ahead for 2026?
Roche concluded 2025 as a company demonstrating resilient performance, strategic focus, and continued innovation across its pharmaceuticals and…
How Did Johnson & Johnson’s 2025 Deals Shape Its Strategy, and What Do They Signal for 2026?
New Brunswick, NJ — In 2025, Johnson & Johnson executed a series of strategic collaborations, acquisitions, and partnerships…
Can Roche’s 2025 Launches and Approvals Reinforce Its Leadership in Oncology, Diagnostics, and Neuroscience Into 2026?
Global | January 2026 — Roche Holding AG achieved a strong year in 2025, marked by multiple regulatory…
Can Novartis’ 2025 Approvals and Launches Strengthen Its Position Across Oncology, Neuroscience, and Rare Diseases Into 2026?
Global | January 2026 — Novartis AG advanced its strategic portfolio in 2025 with multiple product approvals and…
